Venetoclax for AML: changing the treatment paradigm
Author:
Affiliation:
1. Division of Hematology, University of Colorado School of Medicine, Aurora, CO; and
2. Department of Lymphoma and Myeloma and
3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Abstract
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/3/24/4326/1719143/advancesadv2019000937c.pdf
Reference75 articles.
1. SEER . Cancer Statistics Review 2009-2015. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 19 August 2019.
2. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States;Medeiros;Ann Hematol,2015
3. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome;Cortes;Leukemia,2019
4. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts;Dombret;Blood,2015
5. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J Clin Oncol,2012
Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro;Biochemical Pharmacology;2024-02
2. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review;Annals of Hematology;2024-01-29
3. Acute myeloid leukemia;JAAPA;2024-01
4. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216;Blood Advances;2023-12-28
5. The approach of HMA plus VEN with or without BMT for all patients with AML;Hematology;2023-12-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3